Astrin Biosciences has announced the launch of Certitude—a blood-based, early breast cancer detection test. The test combines AI and proteomics in what the company calls a “first of its kind,” because it detects the disease early and works in women with dense breast tissue.

The company says the Certitude supplemental screening test will be available in the U.S. in early 2026 by prescription only.

Dense tissue makes it much harder for mammograms to detect early-stage cancers. Meanwhile, dense breasts are also a significant risk factor for breast cancer. This feature alone gives Certitude an advantage in a market that is estimated to already be worth several billion dollars and to at least double over the next few years, especially as the growing number of young women with breast c

See Full Page